Robert Lafyatis

E-Box Accessibility in Myofibroblasts in Pulmonary Fibrosis

National Heart, Lung, and Blood Institute · R01

PI · $1.5M · University of Pittsburgh at Pittsburgh

Clinical-Translational Studies in Skin, Lung, and Vascular Complications in Systemic Sclerosis

National Institute of Arthritis and Musculoskeletal and Skin Diseases · P50

Contact PI · $7.9M · University of Pittsburgh at Pittsburgh

Pathways Regulating Profibrotic Macrophages in a Novel Explant Model of Systemic Sclerosis-Associated Interstitial Lung Disease

National Institute of Arthritis and Musculoskeletal and Skin Diseases · R21

Contact PI · $347.6K · University of Pittsburgh at Pittsburgh

Mapping Age-Related Changes in the Lung

National Heart, Lung, and Blood Institute · U01

PI · $2.4M · Ohio State University

Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Principal investigator · Terminated · Phase 1

Robert Lafyatis

Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial

Principal investigator · Completed · Phase 1, Phase 2

Prism Pharma Co., Ltd.

Fresolimumab In Systemic Sclerosis

Principal investigator · Completed · Phase 1

Boston University

Mycophenolate Mofetil in Systemic Sclerosis

Principal investigator · Completed · Phase 1

Boston University